Scott Coleman
About Scott Coleman
Scott Coleman is the Chief Development Officer with over 25 years of experience in biotechnology, specializing in drug development across various therapeutic areas including oncology.
Scott Coleman Chief Development Officer
Scott Coleman currently serves as the Chief Development Officer, overseeing all development activities within the organization. With over 25 years of experience in biotechnology and drug development, he has been instrumental in guiding the development and approval of multiple therapies across diverse therapeutic areas, including oncology.
Scott Coleman Education and Expertise
Scott Coleman holds a B.S. in toxicology from Northeastern University and a Ph.D. in toxicology from North Carolina State University. He further honed his expertise through postdoctoral training at the University of Massachusetts Medical School. His extensive educational background provides a solid foundation for his work in biotechnology and drug development.
Scott Coleman Background in Biotechnology
Scott Coleman has a robust background in biotechnology, having contributed to the successful development and approval of various therapies. His recent role as senior vice president of nonclinical development at Xilio underscores his expertise in the field. His experience spans multiple senior scientific roles at notable companies such as Spero Therapeutics, Merck, Cubist Pharmaceuticals, and Millennium Pharmaceuticals.
Scott Coleman Achievements in Drug Development
Scott Coleman has played a significant role in the development and approval of important therapies, including the development of sotatercept. His tenure as vice president of nonclinical development at Acceleron Pharma Inc., up to its acquisition by Merck, highlights his contributions to the field. His efforts have consistently driven successful outcomes in drug development.